Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Nice article
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(290)
•••
Comment by Moonshiner592on May 31, 2020 12:55pm
170 Views
Post# 31093647

RE:Nice article

RE:Nice article

RiskyBiz928 wrote: On the covid bandwagon - just saw the article. Nice Sunday morning surprise. Well, if what they say is true and it actually works and it gets approved... it's gonna get mighty interesting. At least it looks as if it is creating a buzz (15M - nice!). Could see alot of dumping for a few pennies here and there but I would certainly hold on for now. GL all.


... anything COVID related will get the spotlight and be expedited in terms of funds and approvals ... think about it .. we may be dealing with this pandemic for a while  before a vaccine is found for it ... then think about when GVHD is brought into the picture? 

Everything looks to be headed way up north from here!

Buckle up!... and  GLTA 
 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities